MAPT and neuroblastoma: To check the ability of Armanezumab to inhibit neurotoxicity of tau aggregates, we performed cytotoxicity assays to determine whether Armanezumab could protect SH-SY5Y human neuroblastoma cells as well as mouse primary neurons from tau oligomer-mediated neurotoxicity.